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Abstract
Achieving greater continuation of treatment is a key element to improve treatment outcomes
in schizophrenia patients. However, reported treatment continuation can differ markedly
depending on the study design. In a retrospective setting, treatment continuation remains
overall poor among patients using antipsychotics. This study aimed to document the differ-
ence in treatment continuation between four long-acting injectable antipsychotics based on
the QuintilesIMS LRx databases, national, longitudinal, panel based prescription databases
of retail pharmacies, in the Netherlands and Belgium. Paliperidone palmitate once monthly,
risperidone microspheres, haloperidol decanoate, and olanzapine pamoate were studied.
This study demonstrated significantly higher treatment continuation of paliperidone palmi-
tate once monthly compared to risperidone microspheres (p-value<0,01) and haloperidol
decanoate (p-value<0,01) in both countries, a significantly higher treatment continuation of
paliperidone palmitate once monthly compared to olanzapine pamoate in the Netherlands
(p-value<0,01), and a general trend towards better treatment continuation versus olanza-
pine pamoate in Belgium. Analysing the subgroup of patients without previous exposure to
long-acting antipsychotic treatment revealed the positive impact of previous exposure on
treatment continuation with a subsequent long acting treatment. Additionally, the probability
of restarting the index therapy was higher among patients treated with paliperidone palmi-
tate once monthly compared to patients treated with risperidone microspheres and haloperi-
dol decanoate. The data source used and the methodology defined ensured for the first time
a comparison of treatment continuation in a non-interventional study design for the four
long-acting injectable antipsychotics studied.
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Introduction
Treatment continuation used as an indicator of clinical effectiveness in schizophrenia informs
how well a treatment performs in clinical reality [1]. Achieving greater continuation of treat-
ment is a key element to improve treatment outcomes in schizophrenia patients. Treatment
discontinuation has been determined as a reliable and strong predictor of relapse [2–5]; with
each relapse having a detrimental clinical impact [6–8] as well as an important economic bur-
den, considering the high cost of hospitalizations [9]. While a continuous treatment with anti-
psychotic medication has been linked to better outcomes and less risk of relapse [2–5,10],
important differences are often noted between different types of drugs. The use of long-acting
injectable antipsychotic medication (LAAP) has shown in many observational non-interven-
tional studies to be associated with less relapses and lower hospitalization rates after initiation
of treatment as compared to patients treated with oral antipsychotic medication (OAP) [11–
14], resulting in a lower total healthcare cost [15–20].
However, reported treatment continuation can differ markedly depending on the study
design [11]. In a retrospective setting, which can be considered the most “non-interventional”,
as all actions took place in the past with no parties knowing of the ulterior study decision,
treatment continuation remains overall poor among patients using antipsychotics. The major-
ity of patients discontinue treatment in the first few months after initiation [14,21,22]. Retro-
spective study designs are more able to show the superiority of LAAP over OAP in relevant
real-life situations, while less differentiation versus orals is observed in randomized controlled
trials (RCT) design or prospective observational studies [11,23–25]. The main explanation pro-
posed for such differences is the improvement of continuation to treatment, of which adher-
ence is a major driver and which is optimized by protocol in RCTs and prospective
observational studies. Alphs et al.[25], Bossie et al. [23] and Kane et al. [24] therefore recom-
mend using a retrospective design when studying questions related to effectiveness in real clin-
ical practice, as looking back to what already happened is by its very nature non-
interventional.
Not only are differences in clinical effectiveness observed between oral and long-acting
injectable drugs, there are also differences observed between the various available long-acting
injectable drugs. More in particular, recent publications, using observational data, suggest that
paliperidone palmitate once monthly (further referred as PP1M) can result in better treatment
continuation than risperidone microspheres [26,27]. However, this observation was never
tested in a large retrospective dataset.
The main objective of this study was to use real-life data from pharmacy records in order to
compare the ambulatory treatment continuation of patients with schizophrenia after initiation
on one of the four main LAAP used in the Netherlands and Belgium: PP1M, risperidone
microspheres, haloperidol decanoate, and olanzapine pamoate. As patients with continuous
treatment present a lower risk to relapse [2], this study aims at measuring the treatment con-
tinuation for post-discharge ambulatory patients only. A secondary objective was to analyse
treatment following discontinuation and the rate of restart shortly after discontinuation.
Finally, the dosage and combinations with other antipsychotic medications were analysed.
Materials and methods
Panel description
The QuintilesIMS Real-World Data Longitudinal Prescription databases (LRx), are national
databases that combine transactional data from about 1400 retail pharmacies (i.e. approx. 3/4
of pharmacies) in the Netherlands, and over 1600 retail pharmacies in Belgium (i.e. approx. 1/
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3 of pharmacies). Only pharmaceutical products purchased in retail pharmacies are recorded
and no data from the hospital pharmacies are captured. The databases contain actual prescrip-
tion pickup data from pharmacy records for anonymized individual patients. The LRx data-
bases from different countries have already been used to study questions of persistence in
different therapy areas such as diabetes [28], and Hepatitis B [29]. In both countries, the four
drugs analysed are dispensed to non-hospitalized patients through retail pharmacies only,
even in cases when the physician prescribes the drug during a consultation held in the hospital
and when the drug is administered in the hospital. The databases therefore cover appropriately
the treatment purchases of ambulatory patients. As the indication for which the medication is
prescribed cannot be retrieved from the LRx database and knowing the large number of off-
label prescriptions for antipsychotics in general, this was verified in a QuintilesIMS dataset
derived from prescribers of antipsychotics. It was confirmed that LAAP are used predomi-
nantly (> 85%) in psychosis and schizophrenia. As such, the LRx databases can provide valu-
able insights into the use of LAAP for their approved indications.
Patient selection
To optimize data quality, selection criteria were defined in order to address potential missing
data transmissions from pharmacies as well as with patients who only incidentally visited a
pharmacy included in the panel database and therefore cannot be followed longitudinally.
Only data from pharmacies which transmitted data every month were used in the Netherlands.
In Belgium, a maximum of two months of missing data was allowed and within this, only one
month of missing data during the same rolling 12 months. Additionally, patients were required
to have at least one transaction of any drug, either the index drug or any other drug purchased,
within three months following initiation in the Netherlands. In Belgium, patients with only
one transaction of the index drug and with less than three units of any other drug purchased
in a panel pharmacy during the 12 months preceding their first prescription of the index drug
were excluded.
Patients initiating a treatment with PP1M, risperidone microspheres, haloperidol decano-
ate, or olanzapine pamoate were selected. To define patients as newly initiated on the drug,
only those patients that had not purchased the same drug in the 12 months preceding the
index treatment were included. Once patients were selected, all their transactions for 13
months after the initiation date were retrieved. Only treatments in an ambulatory setting were
analysed based on the nature of LRx data, although the treatment may have been started dur-
ing hospitalization prior to inclusion. Two inclusion periods were defined in both countries.
The first inclusion period corresponds to the introduction of PP1M in both countries. Treat-
ment with one of the four drugs had to be initiated between May 2011 and April 2012 in the
Netherlands and between December 2011 and August 2012 in Belgium. To be able to verify
time dependent effects, a second inclusion period, from October 2012 until September 2013 in
the Netherlands and from September 2012 until September 2013 in Belgium was selected. No
phase 4 or observational studies were ongoing in those periods that could have resulted in
patients being included in these datasets.
Age was analysed based on age bands of 5 years. For each cohort, the median age band is
reported.
Treatment continuation
Patients were followed for a total of 13 months after their first prescription of the index drug.
A patient was considered as continuously on treatment either until a complete stop of the
treatment or until the treatment was interrupted for a period longer than the permissible gap.
Retrospective database study of long-acting antipsychotic treatment continuation
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The permissible gap is the maximal time period in which a patient should revisit the phar-
macy to be considered as continuing the index therapy. The permissible gap was defined as:
½coverage period of 1 unit  ½number of units in the last purchase þ ½grace period ð1Þ
The grace period reflects the additional time allowed beyond the coverage period to allow
for deviations from the theoretical prescription frequency. Used grace periods and coverage
periods are provided for each drug in Table 1.
The time to treatment discontinuation of each patient was then calculated as:
½Time between initiation and last purchase before treatment stop þ ½coverage period of 1 unit
 ½number of units in the last purchaseð2Þ
The coverage period for each product was defined based on the summary of product char-
acteristics (SmPC) published by the European Medicines Agency. Initial analysis of the data
revealed that for all drugs, recommendations from the summary of product characteristics
were followed for the majority of patients, with the exception of olanzapine pamoate in the
Netherlands. In the Netherlands, analysis of the gap between two consecutive transactions of
olanzapine pamoate showed that the majority of patients using 405 mg were purchasing one
injection per 14 days, instead of 28 days. For that reason, the duration of 14 days was therefore
used for this strength in the Netherlands only.
A grace period of 28 days was used as base case scenario. Based on the pharmacologic prop-
erties of PP1M and risperidone microspheres extrapolated by Samtani et al. [30], 28 days after
coverage period of the last injection of both drugs, blood concentrations are expected to drop
below therapeutically effective levels.
A sensitivity analysis on the time to treatment discontinuation was carried out by applying
different grace period lengths as indicated in Table 1.
Previous treatment and treatment following discontinuation
Therapy used before the index treatment was analysed based on transactions retrieved during
the three months before initiation of the index drug. Patients were classified per type of previ-
ous treatment by order of priority: patients having purchased long-acting injectable antipsy-
chotics were classified in the first group; among remaining patients, patients who purchased
other antipsychotics were classified in the second group; finally, patients with no transaction
of antipsychotics were classified in the third group.
The potential treatment started after discontinuation of the index drug was collected during
the three months following discontinuation. This analysis was only carried out on patients that
were receiving the index drug for less than ten months. Based on the transactions retrieved
during the three months after discontinuation, patients that purchased the index drug were
classified as restart. Other patients were classified in different groups of treatment using the
same definitions as when analysing the treatment before initiation.
Dosage
For patients with more than one purchase, dosage was analysed at the start and end of the
observed treatment. The dosage at start was defined as the strength of the first injection pur-
chased. If a specific initiation scheme (as defined by SmPC) is used, only the first injection
obtained after the initiation period was used to determine the dose at start of treatment. The
dosage at end of treatment was defined as the strength of the last injection purchased within
the time of continuous medication.
Retrospective database study of long-acting antipsychotic treatment continuation
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Additionally, the average dosage per 28 days was calculated for each patient with more than
one purchase. The average dosage per 28 days was defined as the total number of milligrams
purchased during the observed time on medication, divided by the number of days on medica-
tion, multiplied by 28.
Combination therapy
Combination with other antipsychotic medication was analysed at the first month of treatment
and at the sixth month of treatment. During the first month of treatment, combined medica-
tions were analysed for all patients. During the sixth month of treatment, combined medica-
tions were only analysed for patients still on their index therapy. Combined medication
included all products from the anatomical therapeutic chemical (ATC) class N5A, as defined
by the Ephmra. Use of anticholinergics to treat extrapyramidal side effects was analysed based
on use of trihexyphenidyl and biperiden in the Netherlands and trihexyphenidyl, biperiden
and procyclidine in Belgium, being the available anticholinergics per country.
For each month, based on the purchases of patients during that month, patients were classi-
fied in two groups. Patients with no purchase of other antipsychotic medication were classified
as monotherapy. Patients with purchases of other antipsychotic medication were classified as
combined therapy.
For each month, the percentage of patients using anticholinergics was calculated separately.
Statistics
Differences in time to discontinuation between patient cohorts initiated on different drugs
were analysed using Kaplan-Meier analysis and a Cox proportional hazards regression, con-
trolling for the following covariates: gender, drug strength at treatment initiation, and usage of
co-medication. Hazard ratios with 95% confidence intervals were estimated. The probability
of restarting treatment during the three months following discontinuation was compared
between the different patient cohorts using a logistic regression model with the same covari-
ates. Odds ratios and their 95% confidence intervals were estimated. Statistical significance
was assessed with reference to an a priori α level of 0,05. All statistical tests were performed
using SAS software version 9 (SAS Institute, Cary, NC, USA). Sensitivity analyses were carried
out by varying the grace period (see Treatment continuation, above).
Results
Patient population
Cohort sizes and a description of the patient baseline demographics are represented in Table 2.
The number of patients on olanzapine pamoate is substantially lower than in other cohorts in
Table 1. Treatment durations and grace periods definitions.
PP1M Risperidone microspheres Haloperidol decanoate Olanzapine pamoate
Coverage period (in days) 28 14 28 210mg: 28
300mg: 14 / 28
405mg: NL 14 / BE 28
Grace period (in days)
Base scenario 28 28 28 28
Sensitivity analysis 60 60 60 60
Lower-bound 7 3 7 3 for packs of 14 days; 7 for packs of 28 days
Upper-bound 390 390 390 390
https://doi.org/10.1371/journal.pone.0179049.t001
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both countries and in both periods, which should be considered when drawing conclusions
for this treatment group.
Patients originated from 586 distinct pharmacies in the Netherlands and 1105 distinct phar-
macies in Belgium.
In the Netherlands, the age distribution did not differ greatly between the four drugs stud-
ied. However, in Belgium, median age was in both periods remarkably higher for patients initi-
ated on haloperidol decanoate. Verification in the independent prescription database showed
that long-acting antipsychotics are mostly (>85%) used in psychosis and schizophrenia in Bel-
gium, so it is unlikely that this is due to usage in dementia patients.
Table 2. Patient baseline demographics.
The Netherlands Belgium
PP1M Risperidone
microspheres
Haloperidol
decanoate
Olanzapine
pamoate
PP1M Risperidone
microspheres
Haloperidol
decanoate
Olanzapine
pamoate
First period May11-Apr12 Dec11-Aug12
N 624 540 333 73 481 302 222 43
Gender
Men 383
(61%)
334 (62%) 202 (61%) 55 (75%) 291
(60%)
155 (51%) 91 (41%) 23 (53%)
Women 239
(38%)
203 (38%) 116 (35%) 17 (23%) 182
(38%)
135 (45%) 119 (54%) 20 (47%)
Unknown gender 2 (0%) 3 (1%) 15 (5%) 1 (1%) 8 (2%) 12 (4%) 12 (5%) 0 (0%)
Age
Median age band 38–42 38–42 38–42 38–42 38–42 48–52 68+ 48–52
Previous medication
in ambulatory setting
Other long-acting
injectable
antipsychotics
199
(32%)
13 (2%) 9 (3%) 2 (3%) 187
(39%)
12 (4%) 6 (3%) 1 (2%)
Other oral
antipsychotics
117
(19%)
133 (25%) 95 (29%) 24 (33%) 114
(24%)
92 (30%) 74 (33%) 16 (37%)
No antipsychotic
medication
308
(49%)
394 (73%) 229 (69%) 47 (64%) 180
(37%)
198 (66%) 142 (64%) 26 (60%)
Second period Oct12-Sep13 Sep12-Sep13
N 524 411 373 92 813 568 401 136
Gender
Men 349
(67%)
270 (66%) 205 (55%) 70 (76%) 433
(53%)
241 (42%) 165 (41%) 76 (56%)
Women 172
(33%)
134 (33%) 153 (41%) 20 (22%) 332
(41%)
277 (49%) 206 (51%) 44 (32%)
Unknown gender 3 (1%) 7 (2%) 15 (4%) 2 (2%) 48
(6%)
50 (9%) 30 (7%) 16 (12%)
Age
Median age band 38–42 28–32 28–32 33–37 38–42 48–52 63–67 43–47
Previous medication
in ambulatory setting
Other long-acting
injectable
antipsychotics
76
(15%)
7 (2%) 14 (4%) 2 (2%) 128
(16%)
25 (4%) 22 (5%) 17 (13%)
Other oral
antipsychotics
106
(20%)
109 (27%) 112 (30%) 28 (30%) 235
(29%)
149 (26%) 130 (32%) 35 (26%)
No antipsychotic
medication
342
(65%)
295 (72%) 247 (66%) 62 (67%) 450
(55%)
394 (69%) 249 (62%) 84 (62%)
https://doi.org/10.1371/journal.pone.0179049.t002
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Previous medication can also be found in Table 2. A limited percentage of patients were
previously treated with other long-acting injectable antipsychotics. This percentage is higher
among cohorts initiated on PP1M. Previous treatment in those cases were mostly involving
risperidone microspheres.
The percentage of patients with no previous antipsychotic medication in ambulatory setting
varied between 49% and 73% among the different cohorts in the Netherlands, and between
37% and 69% in Belgium.
Treatment continuation
The time to treatment discontinuation curves are presented in Fig 1. In both periods and both
countries, more patients were able to continue their index drug when initiated on PP1M than
with risperidone microspheres, olanzapine pamoate or haloperidol decanoate. However, for all
treatment groups, observed continuation rates were below 50% after 12 months of follow up in
an ambulatory setting.
Detailed results of the time to treatment discontinuation and of the Cox regression analysis
can be found in Table 3.
In the Netherlands, in both periods, the Cox regression analysis showed a statistically signif-
icant longer time to treatment discontinuation for the PP1M cohort compared to the risperi-
done microspheres, the haloperidol decanoate, as well as the olanzapine pamoate cohorts.
In Belgium, in both periods, the Cox regression analysis showed a statistically significant
longer time on treatment for the PP1M cohort compared to the risperidone microspheres, as
well as the haloperidol decanoate cohorts. The olanzapine pamoate cohorts showed a numeri-
cal but not significant higher risk for treatment discontinuation compared with the PP1M
cohorts.
In both countries, as shown in Table 2, a part of the patients starting a treatment with
PP1M were previously treated with other LAAP, while it was the case for only a very limited
number of patients starting treatment with one of the other drugs. In order to understand the
impact of this variable on the treatment continuation, a second Cox regression analysis was
carried out on the subgroup of patients who were not previously treated with other LAAP. The
time to treatment discontinuation curves for those cohorts are presented in supporting infor-
mation (S1 Fig). Due to the low number of patients, it was not possible to carry out the same
analysis on the subgroup of patients who were previously treated with other LAAP.
As presented in Table 3, the subgroup of patients not previously treated with other LAAP
still showed numerical longer time to treatment discontinuation of PP1M compared to the
other three drugs, but the difference was less pronounced, either by a lower hazard ratio esti-
mation or a higher p-value. The difference in time to treatment discontinuation was significant
only versus risperidone microspheres in both countries and both periods, versus haloperidol
decanoate in Belgium in both periods, and versus olanzapine pamoate in the Netherlands in
the May11-Apr12 period.
Treatment following discontinuation
Table 4 summarizes the treatments received by patients during the first 3 months after discon-
tinuation of their index drug and the results of the logistic regression model.
In the Netherlands, more patients restarted their index drug among patients treated with
PP1M compared to risperidone microspheres and haloperidol decanoate, while numbers were
similar for olanzapine pamoate. Significantly lower probabilities to restart index drug com-
pared to PP1M were found with risperidone microspheres cohort and the haloperidol decano-
ate cohort in the May11-Apr12 period, whereas in the Oct12-Sep13 period, the risperidone
Retrospective database study of long-acting antipsychotic treatment continuation
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microspheres cohort showed a significantly lower probability to restart index drug compared
to PP1M.
In Belgium, within the first 3 months after discontinuation, more patients restarted their
index drug among patients treated with PP1M compared to risperidone microspheres, halo-
peridol decanoate, and olanzapine pamoate. In the Dec11-Aug12 period, compared to PP1M,
the haloperidol decanoate cohort showed a significantly lower probability to restart index
drug. In the Sep12-Sep13 period, the risperidone microspheres cohort and the haloperidol
decanoate cohort showed a significantly lower probability to restart index drug.
Fig 1. Time to treatment discontinuation curves—Base case analysis.
https://doi.org/10.1371/journal.pone.0179049.g001
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In both countries and in both periods, between 23% and 58% of patients did not purchase
any antipsychotic medication in the pharmacy during the 3 months following discontinuation.
Sensitivity analysis
The definition of the grace period has a significant impact on the discontinuation rate. There-
fore, a sensitivity analysis has been conducted to understand the impact of the length of the
permissible gap. The sensitivity analysis on the time to treatment discontinuation for patients
treated with PP1M, risperidone microspheres, haloperidol decanoate and olanzapine pamoate
is presented in Fig 2. Only the results of the second inclusion period are presented here, as
these are similar to those of the first inclusion period.
In all grace period scenarios, the percentage of patients continuing treatment with PP1M is
numerically higher than the percentage of patients continuing treatment with the three other
Table 3. Treatment continuation.
The Netherlands Belgium
PP1M Risperidone
microspheres
Haloperidol
decanoate
Olanzapine
pamoate
PP1M Risperidone
microspheres
Haloperidol
decanoate
Olanzapine
pamoate
First period May11-Apr12 Dec11-Aug12
N 624 540 333 73 481 302 222 43
Percentage of
patients remaining
on treatment
After one injection 91% 88% 85% 88% 83% 69% 62% 81%
After 6 months 59% 42% 42% 25% 43% 26% 18% 23%
After 12 months 31% 21% 24% 11% 23% 14% 11% 14%
Cox regression
analysis (base case)
Hazard ratio Reference 1,50 1,32 2,12 reference 1,60 1,63 1,27
p-value reference <0,01 <0,01 <0,01 reference <0,01 <0,01 0,33
Cox regression analysis (subgroup without patients previously
treated with LAAP)
N 425 527 324 71 294 290 216 42
Hazard ratio Reference 1,29 1,03 2,12 reference 1,35 1,31 1,00
p-value Reference <0,01 0,75 0,01 reference <0,01 0,01 1,00
Second period Oct12-Sep13 Sep12-Sep13
N 524 411 373 92 813 568 401 136
Percentage of
patients remaining
on treatment
After one injection 88% 91% 85% 85% 75% 72% 65% 83%
After 6 months 55% 40% 47% 43% 33% 28% 18% 23%
After 12 months 33% 20% 26% 27% 20% 18% 11% 13%
Cox regression
analysis (base case)
Hazard ratio Reference 1,51 1,19 1,49 reference 1,37 1,45 1,26
p-value Reference <0,01 <0,01 <0,01 reference <0,01 <0,01 0,14
Cox regression analysis (subgroup without patients previously
treated with LAAP)
N 448 404 359 90 685 543 379 119
Hazard ratio Reference 1,29 1,02 1,09 reference 1,28 1,36 1,17
p-value Reference <0,01 0,83 0,70 reference <0,01 <0,01 0,33
https://doi.org/10.1371/journal.pone.0179049.t003
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drugs, except for haloperidol decanoate in the Netherlands using the lower-bound scenario.
Detailed results can be found in supporting information (S1 Table).
Dosage
The median dose per 28 day period was 90–100 mg for PP1M, 72–78 mg for risperidone
microspheres, 97–101 mg for haloperidol decanoate and 406–572 mg for olanzapine pamoate.
The modal start dose equalled modal end dose in most cases. A reduction between mode start
and end dose was found for PP1M in the May11-Apr12 cohort in the Netherlands and for
olanzapine pamoate in the Sep12-Sep13 cohort in Belgium. Few patients, less than 15% in all
Table 4. Treatment following discontinuation.
The Netherlands Belgium
PP1M Risperidone
microspheres
Haloperidol
decanoate
Olanzapine
pamoate
PP1M Risperidone
microspheres
Haloperidol
decanoate
Olanzapine
pamoate
First period May11-Apr12 Dec11-Aug12
N 385 405 234 62 343 254 196 36
Treatment
following
discontinuation
Restart initial drug 161
(42%)
141 (35%) 62 (26%) 27 (44%) 142
(41%)
68 (27%) 33 (17%) 9 (25%)
Other long-acting
injectable
antipsychotics
47 (12%) 39 (10%) 15 (6%) 3 (5%) 24 (7%) 5 (2%) 6 (3%) 0 (0%)
Other oral
antipsychotics
65 (17%) 87 (21%) 63 (27%) 12 (19%) 44 (13%) 47 (19%) 44 (22%) 6 (17%)
No antipsychotic
medication
112
(29%)
138 (34%) 94 (40%) 20 (33%) 133
(39%)
134 (53%) 113 (58%) 21 (58%)
Logistic regression
model
Odds ratio reference 0,70 0,43 0,82 reference 0,71 0,46 0,45
Confidence interval reference 0,54–0,90 0,31–0,58 0,52–1,30 reference 0,49–1,02 0,29–0,74 0,13–1,62
p-value reference <0,01 <0,01 0,39 reference 0,07 <0,01 0,22
Second period Oct12-Sep13 Sep12-Sep13
N 320 303 254 65 622 457 350 114
Treatment
following
discontinuation
Restart initial drug 128
(40%)
101 (33%) 72 (28%) 27 (42%) 228
(37%)
109 (24%) 75 (21%) 39 (34%)
Other long-acting
injectable
antipsychotics
15 (5%) 29 (10%) 8 (3%) 6 (9%) 27 (4%) 26 (6%) 19 (5%) 7 (6%)
Other oral
antipsychotics
49 (15%) 62 (20%) 73 (29%) 17 (26%) 84 (14%) 60 (13%) 52 (15%) 20 (18%)
No antipsychotic
medication
128
(40%)
111 (37%) 101 (40%) 15 (23%) 283
(45%)
262 (57%) 204 (58%) 48 (42%)
Logistic regression
model
Odds ratio reference 0,80 0,58 0,89 reference 0,50 0,47 0,68
Confidence interval reference 0,61–1,06 0,43–0,79 0,56–1,42 reference 0,38–0,68 0,33–0,65 0,39–1,32
p-value reference <0,01 0,12 0,63 reference <0,01 <0,01 0,25
https://doi.org/10.1371/journal.pone.0179049.t004
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Fig 2. Time to treatment discontinuation sensitivity analysis.
https://doi.org/10.1371/journal.pone.0179049.g002
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cases, increased the initial dose. Mode and median dosing are presented in supporting infor-
mation (S2 Table).
Combination therapy
Antipsychotic monotherapy was the norm for all products, as more than 50% of patients used
the product in monotherapy.
Use of medication to treat extrapyramidal side effects after 6 months of therapy with PP1M,
risperidone microspheres, haloperidol decanoate and olanzapine pamoate was respectively
6%, 15%, 26% and 7% in the Netherlands during May11-Apr12 period and 8%, 6%, 22% and
5% during Oct12-Sep13 period. For Belgium these data were 12%, 26%, 52% and 15% during
Dec11-Aug12 period and 7%, 7%, 20% and 8% during Oct12-Sep13 period.
Discussion
This study aimed to document the difference in treatment continuation between four LAAP,
based on data provided by national, longitudinal, panel based prescription databases of retail
pharmacies in the Netherlands and in Belgium. This retrospective study demonstrated a signif-
icantly higher treatment continuation of PP1M compared to risperidone microspheres and
haloperidol decanoate in both countries, a significantly higher treatment continuation of
PP1M compared to olanzapine pamoate in the Netherlands, and a general trend towards better
treatment continuation versus olanzapine pamoate in Belgium. Analysing the subgroup of
patients without previous exposure to long-acting antipsychotic treatment revealed a positive
impact of previous exposure on treatment continuation with a next long acting treatment.
This subgroup analysis demonstrated a significantly higher treatment continuation of PP1M
compared to risperidone microspheres and a general trend towards better treatment continua-
tion versus haloperidol decanoate and olanzapine pamoate, even without previous exposure to
long-acting antipsychotic treatment. Additionally, the probability of restarting the index ther-
apy was higher among patients treated with PP1M compared to patients treated with risperi-
done microspheres and haloperidol decanoate. The low number of patients in the olanzapine
pamoate cohort might have affected the statistical analysis so that only a numerical improve-
ment in treatment continuation and no difference in index therapy restart rate were found
between PP1M versus olanzapine pamoate.
This study demonstrates differences in post discharge treatment continuation, specifically
in the first year of a newly started long-acting medication. While it had already been demon-
strated that long-acting antipsychotics perform better than orals in delaying relapse in real-
world situations [11,12], this study shows that there also exist differences among long-acting
antipsychotics in such real-world circumstances. Although we found that PP1M performed
better than other long acting medications, the clinical significance of this finding needs further
investigation, especially given the usual long periods of psychotic disorder over a patient
lifetime.
On the other hand, in view of the expected channel bias that directed the most severe
patients to the newest medication and the limited available covariates that enable to adjust for
such cohort effects, it is somewhat unexpected that significant differences could be identified
between long-acting treatments with this type of analysis. As a result, although the observed
differences in treatment duration are modest, they do indicate that incremental treatment
extensions between long-acting drugs are possible. This is clinically relevant as continuation of
treatment is a major influence factor on the risk of relapse and discontinuation of medication
increases the relapse risk by a factor of 6 [2]. It remains then an important clinical treatment
aim to reduce the risk of relapse as much as possible, for several reasons. Both the number
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[4,6,31–35] and total duration of subsequent relapses [36] have been linked with worsening of
clinical indicators such as treatment resistance and is, for the patient, not conductive to contin-
uous functioning nor autonomy [8,9,36–39]. One could therefore argue that any relapse delay
is worth the effort from a clinical perspective, and also because it is known that relapses drive
costs through hospitalization cost which is by far the major cost element of schizophrenia
[9,40]. It would be beneficial to perform additional research over longer time periods to further
investigate the clinical benefit of treatment duration extension. In such research, continuous
longitudinal follow-up during periods when the patient is not exposed to medication should
also be included as recent research has shown that a longer half-life of long acting treatments
might result in longer relapse prevention after treatment discontinuation [41]. A growing
amount of data of clinical [42–44], local observational [45–47], product and patient related fac-
tors feed the rationale that PP1M can result in better treatment continuation compared to ris-
peridone microspheres. However, this hypothesis had not been investigated in the context of a
large retrospective real-world database. The intuitively most obvious reason for helping
patients to maintain treatment long-term is a monthly versus biweekly administration. In a
recent study determining the utility of administration interval in schizophrenia as judged by
the general population, Osborne et al. [48] found a statistically significant advantage
(p<0,001) in utility value of monthly (mean utility 0,65) versus biweekly (mean utility 0,61)
administration interval. In addition, differences in convenience and ease of administration
might help as well. Different formulation technology for PP1M resulted in smaller needle size
and increased ease of preparation and storage.
Confirming the results of other studies [22,49], the overall treatment continuation after 1
year remains low. A large number of patients already discontinue in the first few months of
treatment, especially in Belgium.
A first important consideration to explain these findings is that treatment continuation
rates differ depending on the study setting. Typically, retrospective studies demonstrate lower
treatment continuation than prospective studies, because, although even if non-interventional,
there is still the sense of the controlled trial environment, including the contact with the study
center [14,21,22].
Additionally, methodological elements influence the results. All prescription interruptions
longer than the permissible gap period were considered as treatment discontinuations, irre-
spective of the reason for the discontinuation. As the reasons for discontinuation are not avail-
able in the database used, these cannot be investigated. It is also possible that in some cases the
treatment is not ‘de facto’ discontinued, but the patient is, for example, hospitalized. This is
however potentially also a measure of treatment failure and therefore another marker of effec-
tiveness. Any disappearance or interruption beyond the permissible gap period is considered
as a discontinuation in this analysis while the reason is not known. While the above limitations
are a consequence of the database used, methodological parameters like the length of the
‘grace period’ have important consequences as well. The impact of the “grace period”, i.e. how
long a period is accepted after the day the patient should have picked up the next administra-
tion was evaluated in a sensitivity analysis. While careful consideration was given in the selec-
tion of the permissible gap period of the primary analysis (see Materials and methods), more
pragmatic and longer periods might be considered acceptable in clinical practice. Therefore
the sensitivity analyses reflected grace periods of 60 days to 13 months like those applied in
other studies [50,51]. By applying the most stringent parameters in the primary analysis, this
study focused on highly persistent patients, as short time treatment discontinuations are sus-
pected to cause detrimental negative outcomes [52]. One-year continuation rate following
these stringent criteria are considered low. However, continuation rates naturally increased
with increasing grace periods. When the grace period was put more liberal, what could be
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considered as more in line with clinical practice, one-year continuation data approached
results of prospective observational trials. But more importantly, the ranking of the diverse
products in terms of continuation remains consistent and overall results of the primary analy-
sis were confirmed.
Furthermore, it should also be considered that the patient population could represent a
study cohort that is inherently advanced in the severity of their disease. More than 50% of the
patients were not ambulatory treated before a LAAP therapy was started. Following therapy
discontinuation, again 23% to 58% of patients were not visiting the ambulatory pharmacy any
more, although they were visiting a pharmacy while the treatment was ongoing. Additionally,
an important group of the PP1M patients were using long acting medication before they
started the PP1M treatment, indicating the selection bias that occurs when a new product
becomes available: the more advanced patients are being prioritized to the newest available
medication. On the other hand, it must be considered that relatively young patients were also
included in most groups.
Mode start and end dose were well within registered label except for olanzapine pamoate.
When calculating the amount of drug consumed in a 28 day period for comparison reasons,
some discrepancies occur. Risperidone microspheres at 72–78 mg median dose over 28 days in
our study is representative of the recalculated DDD of 75,6 mg per 28 days. Haloperidol decan-
oate is slightly higher at 97–101 mg versus 92,4mg, and PP1M somewhat higher at 93–100 mg
versus 75 mg. The greatest discrepancy is olanzapine pamoate at 406–572 mg versus 280 mg
DDD. We found no evidence of so-called “dose creep”, as dose increases during the study
period were limited to less than 15% of all patients for all products, varying from 0 to 14%
without any visible correlation to country or product.
The remarkably consistent high and generally increasing share of antipsychotic monother-
apy probably reflects the ambulatory nature of the sample. Anticholinergic use reflected the
known pharmacological profiles of the drugs, most notably a higher use of medication to treat
extrapyramidal symptoms with haloperidol decanoate.
Other direct comparisons between long-acting antipsychotics are few. A recent comparison
of haloperidol decanoate and PP1M [53] found no difference in efficacy. However, this study
has been criticized on the account of its high attrition rate, unusual and potentially subjective
measure of “lack of efficacy”, non-equivalent dosing, unclear reporting as well as lack of statis-
tical power [54–56].
Based on the outcomes of the present study, a potential next step might be to develop a
health-economical evaluation study which assesses the health-economical outcomes of the
included long-acting antipsychotics. Recent publications have shown PP1M to be either eco-
nomically dominant (better effectiveness for lower cost) or cost effective [17,19,57–61] versus
risperidone microspheres, olanzapine pamoate, haloperidol decanoate, zuclopentixol decano-
ate or a selection of oral antipsychotics.
Limitations linked to the databases used in this study should be taken into account when
interpreting the results. Firstly, the LRx databases do not provide information on how the
patients use the drugs or on the doctor’s decision to treat. Analysed treatment episodes of
patients are only based on the transactions captured at the pharmacy which are taken as a
proxy for actual use of the product. Continuation of successive transactions is taken as a proxy
for treatment continuation. It may be assumed that if a patient continues to pick up the prod-
uct at the pharmacy, he or she is using it, and that any error size is common to all products.
When a patient discontinues treatment, it is also not known whether the patient continues
consulting his doctor, whether the patient still received a prescription or whether the doctor
decided not to prescribe. Assumptions on the start date of treatment and on the treatment
duration of each pack purchased therefore needed to be made in order to carry out this study.
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However, a limited impact is expected from those assumptions as these are considered to be
equal for all drugs studied. In addition, causal relationships cannot be investigated in this
study. In this analysis, the four groups were not identical at the start of the observation period
due to the observational retrospective design of the study. This is particularly important with
respect to the type of previous medications used. As such baseline differences (e.g. the potential
channel bias that new products are used to treat the most severe patients first) might occur, we
analysed the subgroup of patients that had no previous exposure to long-acting treatment
before starting the index treatment.
Secondly, the most important limitation is linked to the loyalty of patients to their phar-
macy. Patients can indeed visit several pharmacies. This is the case when a patient moves, but
also when a patient occasionally visits another pharmacy than his or her usual pharmacy, or
when a patient regularly visits several pharmacies. In the Netherlands, a unique patient identi-
fier is not in place, which means that a patient who visited two different pharmacies in the
panel during the follow-up period is limited to the first exposure period only. In Belgium,
when a patient changes pharmacy within the panel, there will be no breach in the longitudinal
prescription tracking, as a result of a unique patient identifier in all pharmacies of the LRx
panel. However, if a patient visits a pharmacy in the LRx panel and another out of the LRx
panel, only the first sequence of transactions will be considered in the longitudinal tracking.
The impact of incidental off-panel visits is limited by the grace period and the sensitivity analy-
ses. Eligibility rules have been defined in order to limit the impact of this phenomenon on the
results. However, not all cases of patients changing pharmacy can be detected. As a result,
treatment continuation might have been underestimated. This underestimation cannot be
quantified, but is believed to be limited as a result of a high loyalty among chronic patients to
their pharmacy [62]. Moreover, loyalty to a pharmacy is not dependent on the antipsychotic
used; therefore impact should be similar for all drugs in this study. A reasonable assumption
might be that, due to the high stigma of using antipsychotics and of psychosis itself, patients
prefer the pharmacy that they feel most comfortable with.
The final limitation is related to the continuity in the selection of pharmacies transmitting
data to QuintilesIMS. It is possible that a pharmacy does not transmit data or partially trans-
mits data for a specific month. The transactions of patients visiting those pharmacies during
those months are then missing. Eligibility rules on pharmacies have therefore been defined in
order to monitor data transmissions and select pharmacies for which a sufficient continuity in
the transmissions is observed. Furthermore, long-acting antipsychotics were verified in a pre-
scription-oriented database by QuintilesIMS to be mostly (>85%) used in psychosis and
schizophrenia.
While those limitations can impact the measurement of the treatment continuation, it is
important to note that none of the limitations of the LRx databases are believed to impact the
comparison of treatment continuation between the four long-acting antipsychotic drugs
studied.
Differences in terms of the structure of the database, the number of pharmacies that were
providing data as well as the follow-up care for patients with schizophrenia in both countries
make it impossible to draw robust conclusions when comparing the datasets in both countries.
In conclusion, this study demonstrates that patients stay significantly longer on treatment
when initiated on PP1M compared to risperidone microspheres and haloperidol decanoate. It
also indicated a higher treatment continuation of PP1M over olanzapine pamoate in the Neth-
erlands. Additionally, it shows the positive impact of previous exposure to long-acting treat-
ments on treatment continuation with a next long acting treatment. Despite some limitations,
the data source used and the methodology defined ensure a reliable comparison between the
four products in a real-world setting. As such, this study provides for the first time a
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comparison of the treatment continuation in a large non-interventional study design for the
four long-acting injectable antipsychotics: PP1M, risperidone microspheres, haloperidol
decanoate, and olanzapine pamoate.
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